Neumora Therapeutics, Inc. Common Stock (NMRA) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+121.4%

$1.10

vs $0.50 price

Levered DCF

$1.11

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-18.15

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-1.23×	-6.93×	-11.44×	-18.9×	-10.42×	-25×	0×
P/B	2.82×	5.89×	5.77×	-5.53×	-7.59×	-26.16×	0×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.47×	-6.38×	-9.95×	-17.16×	-8.71×	-23.89×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	5.87×	10.51×	19.05×	16.37×	17.85×	20.69×	0×
Debt / equity	0×	0.01×	0.01×	-0.02×	-0.01×	-0.02×	0×
Interest coverage	-74.92×	0×	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-228.1%	-84.9%	-50.3%	29.3%	73.0%	105.2%	0.0%
Return on invested capital	-151.8%	-91.2%	-39.7%	-33.5%	-58.3%	-50.4%	0.0%
Return on assets	-124.0%	-76.9%	-47.5%	-30.7%	-55.3%	-50.2%	0.0%
Free cash flow yield	-70.6%	-10.8%	-6.0%	-4.7%	-3.1%	-1.1%	0.0%
Earnings yield	-81.0%	-14.4%	-8.7%	-5.3%	-9.6%	-4.0%	0.0%
Enterprise value	$110.4M	$1.5B	$2.3B	$2.2B	$2.1B	$2.3B	$0
Net debt / EBITDA	0.78×	0.58×	1.57×	1.78×	1.72×	1.99×	0×
Cash conversion cycle (days)	-247	0	-184	0	0	0	0